SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-092522
Filing Date
2024-04-11
Accepted
2024-04-11 08:02:54
Documents
14
Period of Report
2024-04-11
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d763719d8k.htm   iXBRL 8-K 25700
2 EX-99.1 d763719dex991.htm EX-99.1 29609
  Complete submission text file 0001193125-24-092522.txt   186366

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA elvn-20240411.xsd EX-101.SCH 2886
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE elvn-20240411_lab.xml EX-101.LAB 17978
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE elvn-20240411_pre.xml EX-101.PRE 11282
17 EXTRACTED XBRL INSTANCE DOCUMENT d763719d8k_htm.xml XML 3629
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

IRS No.: 811523849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39247 | Film No.: 24837165
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)